Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxytrol For Women Draft Questions

This article was originally published in The Tan Sheet

Executive Summary

FDA’s draft questions to the NDAC on Merck’s ’s proposed Rx-to-OTC switch of Oxytrol for Women includes one item to vote on – whether consumers can appropriately self-select the product OTC – while also asking for discussion on possible concerns about safety and about the data included in the firm’s NDA.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel